Virtual | September 22-24, 2022
THURSDAY, SEPTEMBER 22, 2022
8:00 AM – 10:06 AM
SESSION I: PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
State of the Art in Prostate Cancer Screening
10:30 AM – 12:40 PM
SESSION I: PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
Current and Emerging Diagnostic Tools for Improving Risk Assessment, Selection of Patients for Biopsy and Tissue Sampling
Transperineal Prostate Biopsy – Current and Future Clinical Role
NCCN Guidelines for Early Detection of Prostate Cancer 2022
Integrated Multi-Modality Diagnostic Evaluation
12:40 PM – 2:30 PM
LUNCH BREAK
2:30 PM – 3:36 PM
SESSION II. CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
Liquid Markers – Proteomics and Germline Genome
Tissue-Based Genetic Cancer Profiling Overview
Pathology Overview
Current and Future Directions in Risk Assessment: Should Gleason 6 (GG1) be Considered Cancer?
4:00 PM – 5:30 PM
SESSION II. CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
In Vivo Imaging
FRIDAY, SEPTEMBER 23, 2022
8:00 AM – 8:58 AM
SESSION II: CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER (Continued)
In Vivo Imaging (Continued)
Urologic Perspective on the Current and Emerging Role of Multi-Modality Imaging and Radiogenomics
9:30 AM – 11:30 AM
SESSION II: CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER (Continued)
Integration of Precision Diagnosis and Precision Treatment
11:30 AM – 1:30 PM
LUNCH BREAK
1:30 PM – 3:40 PM
SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER
Treatment for Advanced Prostate Cancer, including Oligometastatic and Systemic Disease
4:00 PM – 6:00 PM
SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER
Molecular and Multi-Modality Imaging and Theranostics
SATURDAY, SEPTEMBER 24, 2022
8:00 AM – 9:30 AM
SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT
Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes
10:00 AM – 11:20 AM
SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT
Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes
11:20 AM – 1:00 PM
LUNCH BREAK
1:00 PM – 2:00 PM
PANEL ON BIOINFORMATICS, ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR A MULTIMODALITY DATA ANALYSIS FOR PRECISION DIAGNOSIS AND TREATMENT
2:30 PM – 3:20 PM
PANEL ON PRECISION CARE AND HEALTH DISPARITIES IN PROSTATE CANCER
3:20 PM – 3:50 PM:
PRESENTATION OF WINNING ABSTRACTS
3:50 PM – 5:30 PM
SUMMARY PANEL DISCUSSION – SUMMIT HIGHLIGHTS
5:30 ADJOURN
8:15 am SESSION I: PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
Moderators:
Jim C. Hu, MD, MPH, Ronald P. Lynch Professor of Urologic Oncology and Professor of Urology, Weill Cornell Medical College, Cornell University; and Attending Urologist, New York-Presbyterian Hospital
Laurence Klotz, MD, Professor of Surgery, University of Toronto and Chair of Prostate Cancer Research, Sunnybrook Medical Center, University of Toronto, Canada; and Chair, World Urologic Oncology Federation
Grannum Sant, MD, FRCS, FACS, Professor and Former Chair of Urology, Tufts University School of Medicine; Former Head, Oncology/Urology Medical Affairs, Sanofi, and Rare Genetic Diseases, Genzyme
.
Clare M. C. Tempany-Afdhal, MB BAO BCh, FACR, FISMRM, Ferenc Jolesz MD Professor of Radiology Harvard Medical School; Vice-Chair, Radiology Research Brigham & Women’s Hospital; Director of the Ferenc Jolesz National Center for Image-Guided Therapy & AMIGO; and Chair, Joint American College of Radiology, AdMeTech Foundation and European Society of Urogenital Radiology Steering Committee on PI-RADS Standardization
8:30 am Topic 1: State of the Art and Future Directions in “Smart” Prostate Cancer Screening:
Discussion Chair
Sigrid Carlsson, MD, PHD, MPH, Assistant Attending Epidemiologist, Departments of Surgery (Urology Service) and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center and Associate Professor of Experimental Urology, Sahlgrenska Academy, Gothenburg University, Sweden
8:30 am Risk-Stratified Screening and Early Detection of Prostate Cancer in 2022
Andrew Vickers, PhD, Attending Research Methodologist, Memorial Sloan Kettering Cancer Center
8:36 am PROBASE Trial: Baseline PSA in Young Men (Aged 45 and 50)
Peter Albers, MD, Professor and Chairman, Department of Urology and Medical Director, Comprehensive Cancer Center, University Hospital, Heinrich-Heine-University, Düsseldorf; Professor of Urology and Division Head, Personalized Early Detection of Prostate Cancer, German Cancer Research Center, Heidelberg, Germany; and Chairman, Scientific Congress Office, European Association of Urology
8:42 am Q & A
8:45 am BARCODE1 Trial: Single-Nucleotide Polymorphisms (SNPs)
Jana McHugh, MB BCh BAO MRCPI FFR RCSI, Clinical Research Fellow, Institute of Cancer Research and Honorary Senior Registrar in Clinical Oncology, Royal Marsden Hospital, NHS Foundation Trust, London, United Kingdom
8:51 am IP1-Prostagram Screening Study: Comparing PSA, MRI and Ultrasound
Hashim Ahmed, MD, Professor and Chair, Division of Surgery, Department of Surgery and Cancer, Imperial College London; Honorary Consultant Urological Surgeon, Imperial Urology, Imperial College Healthcare, NHS Trust, United Kingdom
8:57 am Q & A
9:00 am ReIMAGINE Study: Feasibility of MRI-based Screening
Caroline Moore, MD, Professor of Urology, Department of Targeted Intervention, Division of Surgery and Interventional Sciences, University College London, United Kingdom
9:06 am Perspective from European Union and European Association of Urology on Screening: PSA, Risk Calculator, and MRI
Monique Roobol, PhD, Professor of Decision Making in Urology and Head of Scientific Research Office, Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands
9:12 am Q & A
9:15 am Göteborg-2 Trial: PSA Screening Followed by MRI
Jonas Hugosson, MD, Professor and Chief, Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sweden
9:21 am Clinical Trial of STHLM3 and MRI
Martin Eklund, PhD, Associate Professor of Epidemiology, Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Sweden
9:27 am ProScreen: A Randomized Population-Based Screening Trial Combining PSA, Kallikrein Panel and MRI
Anssi Auvinen, MD, PhD, Professor and Head, Department of Epidemiology, Tampere University, Finland
9:33 am Q & A
9:36 am Panel Discussion: “Smart” Prostate Cancer Screening
10:06 am – 10:30 am COFFEE BREAK
10:30 am Topic 2: Current and Emerging Diagnostic Tools for Improving Risk Assessment, Selection of Patients for Biopsy and Tissue Sampling
10:30 am Topic 2A: Current and Emerging Liquid Diagnostics
10:30 am Keynote Address – Clinical Overview
E. David Crawford, MD, Professor of Urology, University of California San Diego; Chairman, Prostate Conditions Education Council; Editor in Chief, Grand Rounds in Urology; and Prostate Cancer Series Editor, Oncology Journal
10:40 am Q & A
10:42 am Serum microRNA for Diagnosis of Prostate Cancer
Shin Egawa, MD, Chairman and Professor, Department of Urology, Jikei University School of Medicine, Japan
10:52 am Q & A
10:54 am Panel Discussion: Liquid Biomarkers
Speakers and Mark Katz, MD, Assistant Professor of Surgery, Boston University School of Medicine
11:04 am Topic 2B: Current and Emerging Imaging Tools and Targeted Biopsies
11:04 am Advanced Ultrasound
Ethan Halpern, MD, Professor and Vice Chair for Research; Co-Director, Prostate Diagnostic Center; and Director, Cardiac CT, Thomas Jefferson University
11:14 am Q & A
11:16 am Multi-Parametric (mp) and Bi-Parametric (bp) Magnetic Resonance Imaging
11:16 am PI-RADS Standardization and Risk Assessment- Recent Advances and Future Plans
Clare M. C. Tempany-Afdhal, MD
11:26 am Q & A
11:28 am Quality Assessment of Prostate MRI: Impact on the Diagnostic Path
Jelle Barentsz, MD, PhD, Chair and Professor of Radiology, Prostate MR Center of Excellence, Nijmegen Medical Center, Radboud University, The Netherlands; and Founding Member and Past-President of the International Cancer Imaging Society, and Past-President of the European Society of Urogenital Radiology
.
11:38 am Q & A
11:40 am MRI-targeted Biopsy of the Prostate for Improved Tissue Sampling
.Mukesh Harisinghani, MD, Director of Abdominal MRI, Massachusetts General Hospital and Professor of Radiology, Harvard Medical School
11:50 am Q & A
11:52 am PRIMARY Trial – The Role of Integrated Molecular and MRI Imaging Prior to Biopsy
Louise Emmett, MD, Professor and Director, Department of Theranostics and Nuclear Medicine, St. Vincent Hospital; and Clinical Research Leader, Garvan Institute of Medical Research, Sydney, Australia
12:02 pm Q & A
12:04 pm Panel Discussion: Imaging Modalities and Targeted Biopsies
12:14 pm Topic 3: Transperineal Prostate Biopsy – Current and Future Clinical Role
12:24 pm Q & A
12:26 pm Topic 4: NCCN Guidelines for Early Detection of Prostate Cancer 2022
Preston Sprenkle, MD, Assistant Professor of Surgery, Yale University School of Medicine; and Member, NCCN Prostate Cancer Early Detection Panel
12:36 pm Q & A
12:40 pm – 2:30 pm LUNCH BREAK
2:30 pm SESSION II: CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER (PART 1)
Moderators:
Matthew R. Cooperberg, MD, MPH, Professor of Urology and Epidemiology & Biostatistics and Associate Chair for Clinical Research, Department of Urology; Helen Diller Family Chair in Urology, UCSF
.
Eric Klein, MD, Fellow, Stanford Distinguished Careers Institute; and Emeritus Professor and Chairman, Glickman Urological and Kidney Institute at Cleveland Clinic (TBC)
.
Jelle Barentsz, MD, PhD
.
3:00 pm Topic 1: Liquid Markers – Proteomics and Germline Genome
Paul Boutros, PhD, MBA, Director of Cancer Data Science, Jonsson Comprehensive Cancer Center; Associate Director of Cancer Informatics at the Institute for Precision Health; and Professor of Urology and Human Genetics, UCLA
3:10 pm Q & A
3:12 pm Topic 2: Tissue-Based Genetic Cancer Profiling Overview
3:22 pm Q & A
3:24 pm Topic 3: Pathology Overview
Thomas M. Wheeler, MD, Director of Surgical Pathology and Cytopathology, Sagis Diagnositcs; Distinguished Emeritus Professor and Immediate Past Chair, Department of Pathology & Immunology, Baylor College of Medicine
3:34 pm Q & A
3:36 pm- 4:00 pm COFFEE BREAK
4:00 pm Topic 4: Current and Future Directions in Risk Assessment: Should Gleason 6 (GG1) be Considered Cancer?
Scott Eggener, MD, Bruce and Beth White Family Professor of Surgery and Radiology, Vice Chair, Section of Urology and Director, High Risk and Advanced Prostate Cancer Clinic, University of Chicago
4:10 pm Q & A
4:12 pm Panel Discussion: Liquid Markers and Tissue Analysis
4:30 pm Topic 5: In Vivo Imaging
4:30 pm Topic 5A: Prostate MRI
4:30 pm Clinical Role of MRI in Staging and Risk Assessment
Peter Choyke, MD, Director, Molecular Imaging, Center for Cancer Research, National Cancer Institute, National Institutes of Health
.
.
4:40 pm Q & A
4:42 pm Prostate Cancer Visibility on MRI: Histopathologic and Genomic Considerations
Andrei Purysko, MD, Clinical Assistant Professor of Radiology, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University; Staff, Section of Abdominal Imaging and Nuclear Radiology, Imaging Institute, Cleveland Clinic; Staff, Glickman Urological and Kidney Institute, Cleveland Clinic
.
.
4:52 pm Q & A
4:54 pm Topic 5B: Molecular Imaging
Andrei H. Iagaru, MD, FACNM, Professor of Radiology – Nuclear Medicine Chief, Division of Nuclear Medicine and Molecular Imaging; and Co-Director, PET-MRI Research Program Stanford University
.
.
.
5:04 pm Q & A
5:06 pm Panel Discussion: MRI and Molecular Imaging
5:16 pm – 5:30 pm GENERAL DISCUSSION
8:00 am SESSION II: CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER (PART 2)
Moderators:
Andrei H. Iagaru, MD, FACNM, Professor of Radiology – Nuclear Medicine Chief, Division of Nuclear Medicine and Molecular Imaging Co-Director, PET-MRI Research Program Stanford University
Adam Kibel, MD, Elliott Carr Cutler Professor of Surgery, Harvard Medical School; Chief of Urology, Brigham and Women’s Hospital and Dana-Farber Cancer Institute
.
Kelvin A. Moses, MD, PhD, FACS, Associate Professor of Urology, Urologic Oncology Fellowship Director, and Director of Comprehensive Prostate Cancer Clinic, Vanderbilt University Medical Center, and Chair, NCCN Prostate Cancer Early Detection Guidelines Panel
Lalitha K. Shankar, MD, PhD, Chief, Clinical Trials Branch, Cancer Imaging Program, National Cancer Institute (TBC)
.
8:00 am Topic 5C: Molecular and Multi-Modality Imaging for Visualization and Staging of the Initial and Recurrent Disease
8:00 am Overview of Non-Invasive and Intraoperative PSMA Imaging
Wolfgang Weber, MD, Professor and Chair, Department of Nuclear Medicine, Klinikum der Isar, Technical University of Munich, Germany
8:10 am Q & A
8:12 am MRI and Biochemical Recurrence
Valeria Panebianco, MD, Associate Professor of Radiology, “Sapienza” – University of Rome; Responsible, Advanced MR & CT Imaging Division & Coordinator, Prostate Unit, Rome, Italy
8:22 am Q & A
8:24 am Axumin Imaging and Biochemical Recurrence
Gerald L. Andriole, MD, Robert Royce Distinguished Professor, Chief of Urologic Surgery, and Vice-Chair, Department of Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, Siteman Cancer Center; and Member, National Comprehensive Cancer Network (NCCN)’s Cancer Early Detection Panel (TBC)
8:34 am Q & A
8:36 am Panel Discussion: Diagnosis of Recurrence
8:46 am Topic 6: Urologic Perspective on the Current and Emerging Role of Multi-Modality Imaging and Radiogenomics
Mohummad Minhaj Siddiqui, MD, Associate Professor of Surgery, Director of Urologic Oncology and Robotic Surgery, University of Maryland Medical System, and Chief of Urology, Baltimore VA Medical Center; and Participant, US Vice President Joseph Biden’s Cancer Moonshot Program
8:56 am Q & A
8:58 am – 9:30 am COFFEE BREAK
9:30 am Topic 7: Integration of Precision Diagnosis and Precision Treatment
9:30 am Topic 7A: Integrated Diagnostics (Radiogenomics) and Active Surveillance: Patient and Monitoring
Sanoj Punnen, MD, MAS, Pap Corps Champions for Cancer Research Endowed Chair in Solid Tumor Research, Associate Professor and Vice Chair of Research, Department of Urology, Co-Chair of Genitourinary Site Disease Group, Sylvester Comprehensive Cancer Center University of Miami, Miller School of Medicine
9:40 am Q & A
9:42 am Topic 7B: Selection and Monitoring of Image-Targeted Minimally Invasive Treatment
Fiona Fennessy, MB, Bch, PhD, Associate Professor of Radiology, Harvard Medical School; Faculty Radiologist, Brigham & Women’s Hospital; Program Director, Cancer Imaging Fellowship Program; and Institute Physician, Dana-Farber Cancer Institute
9:52 am Q & A
9:54 am Topic 7C: Surgical Treatment
Adam Feldman, MD, MPH, Urologist, Massachusetts General Hospital, Assistant Professor of Surgery, Harvard Medical School; and Director, Combined Harvard Urologic Oncology Fellowship
10:04 am Q & A
10:06 am Topic 7D: NCCN Guidelines for Treatment of Localized Prostate Cancer
Kelvin A. Moses, MD, PhD
10:16 am Q & A
10:18 am Panel Discussion: Integration of Precision Diagnosis and Treatment
11:30 am – 1:30 pm LUNCH BREAK
1:30 pm SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER
Moderators:
Peter Choyke, MD
.
.
..
David Nanus, MD, Mark W. Pasmantier Professor of Hematology and Medical Oncology in Medicine, and Director of the New York-Presbyterian Hospital – Weill Cornell Medicine Healthcare System Cancer Program
.
Alan Pollack, MD, PhD, Professor and Chairman of Radiation Oncology, University of Miami Miller School of Medicine; and Service Chief, Radiation Oncology, Jackson Memorial Hospital
.
.
Robert E. Reiter, MD, MBA, Bing Professor in Prostate Cancer; Director, Prostate Cancer Program and Chief, Division of Urologic Oncology; Assistant Dean, Bioentrepreneurship; Department of Urology, David Geffen School of Medicine at UCLA Institute of Urologic Oncology
2:00 pm Keynote Address: Precision Oncology for Prostate Cancer
Charles J. Ryan, M.D, Professor of Medicine, B.J. Kennedy Chair in Clinical Medical Oncology, University of Minnesota; and President and CEO, Prostate Cancer Foundation
2:10 pm Q & A
2:12 pm Topic 1: Treatment for Advanced Prostate Cancer, including Oligometastatic and Systemic Disease
2:12 pm Topic 1A: An Update on the Advanced Prostate Cancer Consensus Conference
Robert E. Reiter, MD, MBA
2:22 pm Q & A
2:24 pm Topic 1B: Standard Treatment and Global Prostate Cancer Issues
Marc Garnick, MD, Director of Cancer Community Services, Network Development, BIDMC, Gorman Brothers Clinical Professor of Medicine at Harvard Medical School; Special Advisor, Oncologic Drugs Advisory Committee of the FDA
.
2:34 pm Q & A
2:36 pm Topic 1C: Immunotherapy: Why do we (mostly) fail?
Arnulf Stenzl, MD, Professor and Chairman, Department of Urology, University of Tuebingen, Germany; Secretary General Adjunct – European Association of Urology; and Member, European Cancer Organization (ECO) Board of Directors
2:46 pm Q & A
2:48 pm Topic 1D: Epigenetic Modulations and Lineage Plasticity
Himisha Beltran, MD, Associate Professor of Medicine, Harvard Medical School and Director of Translational Research, Department of Medical Oncology, Dana-Farber Cancer Institute
.
2:58 pm Q & A
3:00 pm Topic 1E: Radiation Treatment and Its Integration with Precision Diagnostics
3:10 pm Q & A
3:12 pm Topic 1F: Novel Systemic Treatment and Its Integration With Precision Diagnostics
.David Nanus, MD
3:22 pm Q & A
3:24 pm Panel Discussion: Standard and Emerging Treatment
3:40 pm – 4:00 pm COFFEE BREAK
4:00 pm Topic 2: Molecular and Multi-Modality Imaging and Theranostics
4:00 pm Topic 2A: PSMA Imaging – Emerging Clinical Utility
Thomas Hope, MD, Associate Professor of Radiology and Director of Molecular Therapy in the Department of Radiology and Biomedical Imaging; Chair of the Cancer Center’s Molecular Imaging & Radionuclide Therapy Site Committee, University of California, San Francisco; Chief of Nuclear Medicine at the San Francisco VA Medical Center
4:10 pm Q & A
4:12 pm Topic 2B: Theranostics
4:12 pm An overview of PSMA PET for improving patient selection for and outcomes of LuPSMA therapy
Jeremie Calais MD, MSc, Associate Professor, Department of Molecular and Medical Pharmacology; Director, UCLA Theranostics Program, Ahmanson Translational Theranostics Division, University of California, Los Angeles
4:22 pm Q & A
4:24 pm Current State of the Art and Future Vision in Theranostics
Philip Koo, MD, Chief of Diagnostic Imaging and Physician Executive, Northwest Region, Banner MD Anderson Cancer Center
4:34 pm Q & A
4:36 pm Panel Discussion: Molecular Imaging and Theranostics
5:00 pm – 6:00 pm GENERAL DISCUSSION
8:00 am SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT: Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes
Moderators:
David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York
Raja B. Khauli, MD, FACS, Professor of Urology, American University of Beirut Medical Center, Beirut, Lebanon; and Professor of Surgery and Urology, Carle Health, College of Medicine, University of Illinois in Urbana-Champaign
Mitchell Sokoloff, MD, Professor and Chair of Urology, University of Massachusetts School of Medicine
Sadhna Verma, MD, Professor of Radiology, University of Cincinnati College of Medicine
.
Stephen Zappala, MD, Clinical Assistant Professor, Department of Urology, Tufts University School of Medicine
.
8:30 am Overview
Jurgen Fütterer, MD, PhD, Interventional Radiologist, Professor of Image-guided Interventional Oncology, Radboud University Medical Center, Nijmegen, and Professor, Robotics and Mechanics Group, University of Twente, The Netherlands
8:40 am Q & A
8:42 am Current Clinical Trials
John Feller, MD, Chief Medical Officer, HALO Diagnostics; and Assistant Clinical Professor of Radiology, Loma Linda University School of Medicine
8:52 am Q & A
8:54 am MRI Standardized Reporting for Focal Therapy Planning and Follow-up
Daniel Margolis, MD, Associate Professor of Radiology, Director, Prostate MRI, and Chair, Weill Cornell Institutional Review Board, Weill Cornell Medical College, Cornell University
9:04 am Q & A
9:06 am Micro-Ultrasound and Focal Laser Ablation at the University of Toronto
Sangeet Ghai, MD, Associate Professor, Department of Medical Imaging, University of Toronto, Canada
9:16 am Q & A
9:18 am Image-Guided Laser Ablation – Experience at the University of Chicago
Aytekin Oto, MD, Professor and Chairman of Radiology, University of Chicago
9:28 am Q & A
9:30 am – 10:00 am COFFEE BREAK
10:00 am Image-Guided High Intensity Focal Ultrasound – Recent Clinical Trials
Steven Raman, MD, Clinical Professor of Radiology and Director of Prostate MR Imaging and Interventions, David Geffen School of Medicine, UCLA
10:10 am Q & A
10:12 am Sight and Switch off: Nerve Density Visualization for Interventions Targeting Prostate Cancer
Liang Wang, MD, PhD, Professor, Attending Radiologist, Vice-Chairman for the Research and Development, Director of Urogenital Imaging, Department of Radiology, Beijing Friendship Hospital Capital Medical University, China
10:22 am Q & A
10:24 am Urologic Perspective on Clinical Utility and Outcomes: The Importance of Close Collaboration between Radiology and Urology
Geoffrey Sonn, MD, Assistant Professor of Urology and Radiology, Stanford University School of Medicine
10:34 am Q & A
10:36 am Radiation Oncology Perspective
Daniel Y. Song, MD, Professor of Radiation Oncology and Molecular Radiation Sciences, and Co-Director, Prostate Cancer Multi-Disciplinary Clinic, Johns Hopkins University
10:46 am Q & A
10:48 am Panel Discussion: Image-Guided Treatment
11:20 am – 1:00 pm LUNCH BREAK
1:00 pm PANEL ON BIOINFORMATICS, ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR A MULTI- MODALITY DATA ANALYSIS FOR PRECISION DIAGNOSIS AND TREATMENT
Moderators:
Paul Boutros, PhD, MBA
Arnold C Cinman, MD, FACS, Partner, Tower Urology; and Attending Urologist, Cedars-Sinai Medical Center, Los Angeles
Masoom Haider, MD, Professor of Radiology, University of Toronto; Senior Clinician Scientist, Lunenfeld Tanenbaum Research Institute; Director, Machine Learning and Radiomics Lab; and Director, Sinai Health System Research MRI, Canada
Michael H. Johnson, MD, Vice Chief of Urology, Washington University, St. Louis
Christoph Wald, M.D., Ph.D., M.B.A., F.A.C.R., Professor and Chairman of Radiology, Lahey Hospital and Medical Center, Tufts University Med School; and Chair, Informatics Commission, American College of Radiology
1:00 pm Personalization of Prostate Cancer Care through Integration of Data
Ilya Gipp, MD, PhD, Oncology Solutions Subject Matter Expert, Philips
1:10 pm Q & A
1:12 pm Radiologic Perspective on the Emerging and Potential Role of Machine Learning
Masoom Haider, MD
1:22 pm Q & A
1:24 pm Personalized And Population Specific Computational Imaging Approaches for Prostate Cancer Diagnosis And Prognosis
Rakesh Shiradkar, PhD, Research Assistant Professor, Biomedical Engineering, Case Western Reserve University, Member, Case Comprehensive Cancer Center
1:34 pm Q & A
1:36 pm Development of New Approaches Using Artificial Intelligence for Segmentation of Dominant Index Lesion in Prostate Cancer
Amita Dave, PhD, Attending Physicist and Deputy Service Chief for Predictive Informatics, Director of Quantitative Imaging, Memorial Sloan Kettering Cancer Center
Harini Veeraraghavan, Ph.D, Associate Attending Computer Scientist, Department of Medical Physics, Memorial Sloan Kettering Cancer Center
1:46 pm Q & A
1:48 pm Panel Discussion: Bioinformatics, Artificial Intelligence and Machine Learning
2:00 pm – 2:30 pm COFFEE BREAK
2:30 pm PANEL ON PRECISION CARE AND HEALTH DISPARITIES IN PROSTATE CANCER
Moderators:
Adam B Murphy, MD, MBA, MSCI, Assistant Professor, Department of Urology & Preventive Medicine, Northwestern Medicine – Feinberg School of Medicine, Affiliate Member of Institute for Global Health and Center for Community Health
Quoc-Dien Trinh, MD, Co-Director, Dana-Farber/Brigham and Women’s Prostate Cancer Program; Director, Ambulatory Clinical Operations, Division of Urological Surgery; and Associate Professor of Surgery, Harvard Medical School
2:30 pm Overview of Emerging Data
Quoc-Dien Trinh, MD
2:40 pm Q & A
2:42 pm Current State of Knowledge – Genomics and Health Disparities
Yaw Nyame, MD, MS, MBA, Assistant Professor, Department of Urology, University of Washington; Program Lead, Office of Community Outreach and Engagement and Affiliate Assistant Member, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center
2:52 pm Q & A
2:54 pm Current and Emerging Approaches to Prostate Cancer Inequities
Adam B Murphy, MD
3:04 pm Q & A
3:06 pm Panel Discussion: Health Disparities
3:20 pm – 3:50 pm Presentation of Winning Abstracts
3:50 pm – 5:30 pm SUMMARY PANEL DISCUSSION – SUMMIT HIGHLIGHTS
5:30 pm ADJOURN